Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
The American College of Rheumatology (ACR) and the American College of Hip Surgery (AAHKS) have released new guidelines.
Read Full NewsResearchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.
For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.
Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
1.
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis
2.
a brand-new generic therapy for different types of cancer.
3.
Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?
4.
Implant-based reconstruction linked to increased risk of breast lymphomas
5.
Prior authorizations draining time, energy from many cancer patients
1.
Targeting the Tumor Microenvironment: Next-Generation Strategies for Immuno-Oncology Success
2.
Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians
3.
Innovative Marketing Strategies for Oncology Drugs: A Clinician’s Take on Digital and B2B Trends
4.
The Importance of Corrected Calcium Levels in Managing Health Conditions
5.
The importance of understanding normal serum osmolality
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Lung Cancer Congress®
3.
Genito-Urinary Oncology Summit 2026
4.
Future NRG Oncology Meeting
5.
ISMB 2026 (Intelligent Systems for Molecular Biology)
1.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Navigating the Complexities of Ph Negative ALL - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge